Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea · Delayed Price · Currency is KRW 33,250
+950 (2.94%)
At close: Aug 24, 2026
Next Biomedical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 17,789 | 16,477 | 9,543 | 4,882 | 2,795 | 2,267 |
Other Revenue | - | -0 | - | - | -0 | - |
| 17,789 | 16,477 | 9,543 | 4,882 | 2,795 | 2,267 | |
Revenue Growth | 46.25% | 72.67% | 95.46% | 74.67% | 23.28% | 0.29% |
Cost of Revenue | 5,312 | 5,028 | 3,787 | 2,813 | 2,618 | 2,998 |
Gross Profit | 12,477 | 11,449 | 5,755 | 2,069 | 177.49 | -731.09 |
Selling, General & Admin | 6,564 | 4,465 | 2,610 | 2,407 | 2,246 | 2,866 |
Research & Development | 8,033 | 7,581 | 6,622 | 4,783 | 3,579 | 3,245 |
Amortization of Goodwill & Intangibles | 12.12 | 11.96 | 22.71 | 31.02 | 34.25 | 31.6 |
Other Operating Expenses | 56.63 | 26.03 | 21.51 | 20.04 | 19.29 | 18.39 |
Operating Expenses | 14,774 | 12,169 | 9,330 | 7,296 | 5,946 | 6,239 |
Operating Income | -2,298 | -719.54 | -3,575 | -5,226 | -5,768 | -6,970 |
Interest Expense | -270.54 | -367.31 | -520.06 | -574.37 | -360.41 | -1,413 |
Interest & Investment Income | 988.8 | 926.51 | 634.82 | 574.31 | 200.41 | 138.66 |
Currency Exchange Gain (Loss) | 802.64 | -108.1 | 1,128 | 0.56 | 63.63 | 90.33 |
Other Non Operating Income (Expenses) | -61.75 | 24.61 | 5,074 | -2,429 | 268.61 | -8,494 |
EBT Excluding Unusual Items | -838.39 | -243.82 | 2,742 | -7,655 | -5,596 | -16,648 |
Gain (Loss) on Sale of Investments | 1,070 | -77.07 | 113.58 | 133.56 | -102.48 | -65.86 |
Gain (Loss) on Sale of Assets | 0.48 | 9.81 | 4.24 | - | 5.29 | 69.58 |
Asset Writedown | - | - | - | - | -38.72 | -0.8 |
Pretax Income | 232.56 | -311.08 | 2,860 | -7,522 | -5,732 | -16,645 |
Net Income | 232.56 | -311.08 | 2,860 | -7,522 | -5,732 | -16,645 |
Net Income to Common | 232.56 | -311.08 | 2,860 | -7,522 | -5,732 | -16,645 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 8 | 8 | 7 | 6 | 6 | 5 |
Shares Outstanding (Diluted) | 8 | 8 | 7 | 6 | 6 | 5 |
Shares Change | 2.72% | 12.84% | 14.72% | 1.10% | 28.34% | 13.05% |
EPS (Basic) | 28.46 | -38.27 | 397.00 | -1198.00 | -923.00 | -3440.00 |
EPS (Diluted) | 28.46 | -38.27 | 397.00 | -1198.00 | -923.00 | -3440.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -180.14 | -1,902 | -1,640 | -4,225 | -8,403 | -6,101 |
Free Cash Flow Per Share | -22.05 | -233.95 | -227.68 | -672.87 | -1353.18 | -1260.87 |
Gross Margin | 70.14% | 69.49% | 60.31% | 42.38% | 6.35% | -32.25% |
Operating Margin | -12.92% | -4.37% | -37.46% | -107.05% | -206.37% | -307.42% |
Profit Margin | 1.31% | -1.89% | 29.97% | -154.06% | -205.07% | -734.13% |
Free Cash Flow Margin | -1.01% | -11.54% | -17.18% | -86.53% | -300.65% | -269.08% |
EBITDA | -1,764 | -201.04 | -3,082 | -4,759 | -5,305 | -6,537 |
EBITDA Margin | -9.92% | -1.22% | -32.30% | -97.48% | -189.79% | -288.30% |
D&A For EBITDA | 533.61 | 518.51 | 492.36 | 467.32 | 463.41 | 433.53 |
EBIT | -2,298 | -719.54 | -3,575 | -5,226 | -5,768 | -6,970 |
EBIT Margin | -12.91% | -4.37% | -37.46% | -107.05% | -206.37% | - |
Advertising Expenses | - | 114.55 | 171.98 | 196.9 | 59.64 | 76.25 |